Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation
ME.13, a CCTG-led randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP) - was centrally activated on July 4, 2016.

This is a pragmatic study testing the administration of publicly-funded PD-1 inhibitors intermittently vs. continuously in a non-inferiority design.

The sample size is 500 patients.

Interested centres should contact Ms. Dora Nomikos, Team Leader, at dnomikos@ctg.queensu.ca.

For more information about this trial, please visit the trial website at https://www.ctg.queensu.ca/trials/melanoma/me13/.